Funding agencies: This work was supported by the Basic Science Research Program through the National Research Foundation (NRF) of Korea as funded by the Ministry of Education, Science and Technology (MEST) (No. 2010-0029460).
Article first published online: 23 SEP 2011
Copyright © 2011 Movement Disorder Society
Volume 26, Issue 13, pages 2364–2370, November 2011
How to Cite
Lee, H.-W., Choi, J. and Suk, K. (2011), Increases of pentraxin 3 plasma levels in patients with Parkinson's disease. Mov. Disord., 26: 2364–2370. doi: 10.1002/mds.23871
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 22 NOV 2011
- Article first published online: 23 SEP 2011
- Manuscript Accepted: 15 JUN 2011
- Manuscript Revised: 6 JUN 2011
- Manuscript Received: 28 FEB 2011
Additional Supporting Information may be found in the online version of this article.
|MDS_23871_sm_SuppFig1.tif||335K||Supplementary Figure 1. ROC curve analysis. ROC analysis was conducted to compare the plasma PTX3 levels in the control and PD patients.|
|MDS_23871_sm_SuppFig2.tif||286K||Supplementary Figure 2. Correlation between the PTX3 plasma levels and the Schwab & England ADL scale and the H&Y stage in the PD patients (n=66). After adjusting for age and comorbidity, the PTX3 levels showed significant negative correlations with the Schwab & England ADL scale (r = - 0.277; p = 0.027) (A). There was no significant correlation between the PTX3 levels and the H&Y stage (r = 0.169; p = 0.183) (B).|
|MDS_23871_sm_SuppFig3.tif||274K||Supplementary Figure 3. Correlation between the plasma levels of PTX3 and the disease duration in the PD patients (n = 66). After adjusting for age and comorbidity, there was no significant correlation between the PTX3 levels and the disease duration in the PD patients (r = - 0.032, p = 0.801).|
|MDS_23871_sm_SuppFig4.tif||267K||Supplementary Figure 4. Measurement of the plasma levels of PTX3 in the control subjects (n = 41) and the PD (n = 66), MSA (n = 9) and PSP (n = 5) patients. The PTX3 plasma levels were determined by specific Sandwich ELISA. The horizontal bar in each column indicates the mean values of the PTX3 levels, with statistically significant differences between the groups indicated by the p values after adjustment for age, gender and comorbidities.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.